Skip to content

Medical management of refractory mastalgia

Complete estrogen blockade in recalcitrant mastalgia:A randomized clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030359
Enrollment
40
Registered
2021-01-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Severe Mastalgia (true breast pain) not responding to three months of treatment with first line drugs (danazol, centchroman, tamoxifen)

Interventions

Intervention1: Injection Leupride and Tablet Cenchroman: Depot Injection leupride 3.75 mg will be given subcutaneously for three doses at 0,1,2 months with a daily dose of Tablet centchroman 30 mg onc

Sponsors

All India Institute of Medical Sciences Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women giving consent with recalcitrant mastalgia, normal menstrual cycles, non pregnant, no personal history of breast or ovarian cancer.

Exclusion criteria

Exclusion criteria: Cancer breast/ovary, Pregnancy, breast feeding or lady desiring pregnancy in next 6 months, Lady with PCOD or cervical hyperplasia, Lady not giving consent

Design outcomes

Primary

MeasureTime frame
Relief of pain in to a VAS score of 3 or less at 4 weeks of starting treatmentTimepoint: Relief of pain in to a VAS score of 3 or less at 4 weeks of starting treatment

Secondary

MeasureTime frame
To compare the safety and patient compliance of complete estrogen blockade using LHRH analogue and centchroman with LHRH analogue and tamoxifen when given as a therapy for recalcitrant mastalgia.Timepoint: 03 months

Countries

India

Contacts

Public ContactSuhani

All India Institute of Medical Sciences

drsuhani@gmail.com9810534358

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026